Search - tctmd.com

Displaying 1 - 20 of 93

Sort: Relevancy | Date

Presentation AHA 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presenter: Steven E. Nissen

November 18, 2024

Presentation AHA 2024

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

Presenter: Marcely Gimenes Bonatto

November 18, 2024

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

Presentation AHA 2024

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Presenter: Milton Packer

November 16, 2024

Presentation TCT 2024

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

Presenter: Ryo Hikida

October 29, 2024

Presentation TCT 2024

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Presenter: David Kwon

October 29, 2024

Presentation TCT 2024

Leadership Roles – Chief of Cardiology or Hospital-level Service Line Director: What Does this Entail and Do I Want It?

Presenter: Samir Kapadia

October 29, 2024

Presentation TCT 2024

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Presenter: Raymond Townsend

October 29, 2024

Presentation TCT 2024

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

Presenter: Michael Weber

October 29, 2024

Presentation TCT 2024

Debate Con: Predictors of Efficacy are Sorely Needed in the RDN Space!

Presenter: Eric Secemsky

October 29, 2024

Presentation TCT 2024

What Evaluation is Required for Patient Selection for RDN?

Presenter: Naomi Fisher

October 29, 2024

Presentation TCT 2024

How to Set Up Your RDN Hypertension Program: Team Members and Patient Flow

Presenter: Michael Bloch

October 29, 2024

Presentation TCT 2024

Transcatheter vs. Surgical Aortic Valve Replacement in Women: A Pooled Analysis of the RHEIA and PARTNER 3 Trials

Presenter: Didier Tchetche

October 29, 2024

Presentation TCT 2024

The ALIGN-AR Trial: Two-Year Outcomes of Transcatheter Aortic Valve Replacement With JenaValve TrilogyTM in High Surgical Risk Patients With Moderate-to-Severe or Severe Native Aortic Regurgitation

Presenter: Torsten Vahl

October 29, 2024

Presentation TCT 2024

TCT 1519: Virtual Reality Revolutionizing Structural Cardiology: Pre-Procedural ASD Closure Done in a 3D Model

Presenter: Pablo Barzallo

October 29, 2024

Presentation TCT 2024

Comparison of Strategies for Vascular Access Closure After Transcatheter Aortic Valve Implantation: The ACCESS-TAVI Randomized Trial

Presenter: Tobias Rheude

October 29, 2024

Presentation TCT 2024

Colchicine in Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement: A Double-Blind Randomized Controlled Trial

Presenter: Thomas Pilgrim

October 29, 2024

Presentation TCT 2024

Cerebral Embolic Protection in the US Cohort of the PROTECTED TAVR Trial

Presenter: Samir Kapadia

October 29, 2024

Presentation TCT 2024

What’s Next - Going into 2025

Presenter: Vijay Iyer

October 28, 2024

Presentation TCT 2024

Science of Ultrasound RDN

Presenter: Michael Joner

October 28, 2024

Advertisement

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Leadership Roles – Chief of Cardiology or Hospital-level Service Line Director: What Does this Entail and Do I Want It?

Debate Pro: RDN Could Be Useful for the Majority of Patients with Uncontrolled HTN

Debate Pro: Predictors of Efficacy are Not Needed for Most Patients

Debate Con: Predictors of Efficacy are Sorely Needed in the RDN Space!

What Evaluation is Required for Patient Selection for RDN?

How to Set Up Your RDN Hypertension Program: Team Members and Patient Flow

Transcatheter vs. Surgical Aortic Valve Replacement in Women: A Pooled Analysis of the RHEIA and PARTNER 3 Trials

The ALIGN-AR Trial: Two-Year Outcomes of Transcatheter Aortic Valve Replacement With JenaValve TrilogyTM in High Surgical Risk Patients With Moderate-to-Severe or Severe Native Aortic Regurgitation

TCT 1519: Virtual Reality Revolutionizing Structural Cardiology: Pre-Procedural ASD Closure Done in a 3D Model

Comparison of Strategies for Vascular Access Closure After Transcatheter Aortic Valve Implantation: The ACCESS-TAVI Randomized Trial

Colchicine in Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement: A Double-Blind Randomized Controlled Trial

Cerebral Embolic Protection in the US Cohort of the PROTECTED TAVR Trial

What’s Next - Going into 2025

Science of Ultrasound RDN

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content